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Waldenstrom Macroglobulinemia with CD5+ Expression Presented 
as Cryoglobulinemic Glomerulonephropathy: A Case Report
Waldenstrom macroglobulinemia (WM) is a B-cell lymphoproliferative disorder associated 
with bone marrow involvement of lymphoplasmacytic lymphoma (LPL) and an IgM 
monoclonal gammopathy. Generally B-lymphocytes in LPL do not express CD5 that is 
important for differential diagnosis of B-cell lymphoproliferative disorders. In WM, various 
renal diseases and type I cryoglobulinemia are well described separately, but 
cryoglobulinemic glomerulonephropathy is very rarely reported. A 61-yr-old woman 
complained of generalized edema, cyanosis of the extremities in cold weather, visual 
disturbance, and pancytopenia. Bone marrow and renal biopsy showed CD5+ expressing 
B-cells and cryoglobulinemic glomerulonephropathy. With the diagnosis of WM, she 
received cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy 
and got complete remission. Here, we report a rare case of WM associated with unusual 
expression of CD5+ B-lymphocytes and cryoglobulinemic glomerulonephropathy, and 
emphasize the importance of the clinical features in differentiating CD5+ B-cell 
lymphoproliferative disorders.
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CASE REPORT
Oncology & Hematology
INTRODUCTION
Waldenstrom macroglobulinemia (WM) is a rare plasma cell dis-
order characterized by lymphoplasmacytic infiltration of bone 
marrow and by the demonstration of an IgM paraproteinemia 
(1). By the definition of the World Health Organization (WHO) 
and the Revised European-American Lymphoma (REAL) clas-
sification criteria, WM is classified as an indolent form of B-cell 
non-Hodgkin’s lymphoma known as lymphoplasmacytic lym-
phoma (LPL) (2). LPL is a neoplasm of small B lymphocytes, 
plasmacytoid lymphocytes, and plasma cells, with variable num-
bers of immunoblasts (3). In LPL, small B lymphocytes are usu-
ally negative for CD5, CD10, and CD23, so LPL is presumed to 
derive from CD5 negative peripheral B lymphocytes stimulated 
to differentiate to plasma cells (4). In WM, only approximately 
5%-20% of cases had CD5 positivity (5). The incidence of WM is 
not recognized in Asia, and LPL constitutes less than 5% of all 
non-Hodgkin lymphomas and is extremely rare in patients of 
East Asia (4). So the incidence of WM of CD5 positive LPL in Asia 
is guessed to be very uncommon.
  On the other hand, clinical features of WM are associated with 
tissue infiltration by neoplastic cells and IgM monoclonality (6). 
In WM, renal disease and type I cryoglobulinemia are well rec-
ognized, separately, but cryoglobulinemic glomerulonephrop-
athy is very rare and only 2 cases have been reported worldwide 
(7, 8). 
  Now we report a rare case of WM associated with CD5+ LPL 
and presented as cryoglobulinemic glomerulonephropathy. 
CASE DESCRIPTION
On April 24, 2009, a 61-yr-old woman visited our hospital with 
generalized edema for 3 months. She also complained of tin-
gling sensation and cyanosis of extremities in cold weather and 
visual disturbance. Physical examination showed mild anemic 
conjunctivae, splenomegaly and pretibial pitting edema on both 
legs. But there were no superficial lymph nodes and hepatomeg-
aly. The laboratory findings revealed white blood cells, 3,270/
μL (segment neutrophil 57%; lymphocytes 28%); hemoglobin, 
8.8 g/dL; and platelets, 81,000/μL. Blood urea nitrogen, serum 
creatinine, total protein and albumin were 28.2 mg/dL, 1.4 mg/
dL, 5.7 g/dL and 3.0 g/dL, respectively. In urinalysis, 4+ of pro-
teinuria and 3+ of hematuria were found. Bence-Jones proteins 
were not found in urine. ANA was positive (1:640, speckled) and 
anti-ds DNA antibody was negative. The serum levels of IgG, 
IgA were normal (IgG, 972.47 mg/dL [normal 970-1,700 mg/dL], 
IgA, 242.07 mg/dL [normal 110-410 mg/dL]) but IgM was slight-
ly elevated (246.41 mg/dL [normal 35-220 mg/dL]). C3 was 55.45 Kim YL, et al.  •  Waldenstrom Macroglobulinemia 
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mg/dL (normal 86-160 mg/dL) and C4 was 1.6 mg/dL (normal 
17-45 mg/dL). Serum LDH was 300 IU/L. HBsAg, anti-HBs and 
anti-HCV were all negative. In renal biopsy, we found that the 
glomeruli are generally enlarged showing marked endocapillary 
proliferation and irregularly thickened capillary wall with fre-
quent obliteration of the capillary lumen due to pseudothrombi 
and subendothelial hyaline deposits with stained IgM. On the 
electron microscopic (EM) findings, there are subendothelial 
and mesangial electron dense deposits revealing microtubular 
structures compatible with cryoglobulinemic glomerulone-
phropathy (Fig. 1). In additional tests, cryoglobulin was positive 
and the level of β2-microglobulin was 4.4 mg/L (normal 0-2.4 
mg/L). Monoclonal gammopathy with IgM kappa type was seen 
in immunofixation electrophoresis (Fig. 2A). Bone marrow bi-
opsy revealed small lymphocytes with expression of CD5+CD20+ 
suggestive of B-cell lymphoproliferative disorders and positive 
reaction in small numbers of plasma cells with anti-cytoplasmic 
IgM antibody (Fig. 3). Ophthalamic examination showed vascu-
lar segmentation and dilatation of the retinal veins (Fig. 4) and 
PET-CT showed no abnormal hypermetabolic lesions. Thus, on 
the basis of symptoms, signs, the laboratory findings, renal bi-
opsy and bone marrow examination, we diagnosed WM. She 
was treated with cyclophosphamide, doxorubicin, vincristine 
and prednisolone (CHOP) chemotherapy. After the treatment, 
A B
Fig. 1. Renal biopsy. (A) Immunofluorescent microscopic study showed 2+ reaction for IgM. (B) On the electron microscopic (EM) findings (× 20,000), there are subendothelial 
(arrow) and mesangial electron dense deposits revealing microtubular structures (25 nm in average diameter). 
Fig. 2. Serum immunofixation electrophoresis. (A) There is a slightly dense band with IgM, kappa antisera, suggestive of monoclonal gammopathy (B) After the treatment, a dense 
band with IgM was disappeared.
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we observed negative proteinuria, hematuria, serum cryoglob-
ulin and monoclonal gammopathy in immunofixation electro-
phoresis (Fig. 2B). Complete blood cell profiles were normal-
ized and lymphoid cell aggregation in bone marrow was absent. 
And she also had improved visual acuity and tingling sensation 
of upper and lower extremities. 
 
DISCUSSION
According to the criteria of Waldenstrom Macroglobulinemia 
(WM) revised in the 4th edition of the WHO classification in 
2008, the definition of WM combines the morphological diag-
nosis of bone marrow involvement of lymphoplasmacytic lym-
Fig. 4. Ophthalmoscopic examination revealed dilatation and tortuosity of the retinal 
veins. 
A B
Fig. 3. Bone marrow biopsy. (A) Positive reaction in small lymphocytes with anti-CD5 antibody (immunohistochemical stain, × 400). (B) Positive reaction in small numbers of 
plasma cells with anti-cytoplasmic IgM antibody (immunohistochemical stain, × 400).  
phoma (LPL) with IgM paraproteinemia (9). Owing to histolog-
ical overlapping between lymphoplasmacytic lymphoma and 
other mature B-cell malignancies with plasmacytic differentia-
tion, immunophenotyping is invaluable in the differential diag-
nosis of B-cell lymphoproliferative disorders, and in all cases of 
suspected WM it is needed to apply (5). The special immuno-
phenotypic profile for lymphoplasmacytic cells in WM include 
the expression of monoclonal immunoglobulin light chain (κ 
and λ and the pan B-cell antigens CD19+CD20+ (1). The major-
ity of cases have CD5-CD10-CD23-, but 5%-20% of patients ap-
pear to express the CD5 antigen (10). Although the expression 
of CD5+ in LPL/WM is uncommon, this should not preclude a 
diagnosis of WM. However, the attention should be paid to di-
agnose the CD5+ cases to exclude chronic lymphocytic leuke-
mia and mantle cell lymphoma. 
  In bone marrow examination of our patient, small lymphoid 
cells expressed CD5+CD20+ and positive reaction in small num-
bers of plasma cells with anti-cytoplasmic IgM antibody was 
observed. Because of CD5+ small lymphoid cells, the careful at-
tention for symptoms and signs was important to differentiate 
from other B-cell lymphoproliferative disorders. Comparing to 
chronic lymphocytic leukemia, peripheral blood lymphocyte 
count of this patient was not compatible with the diagnostic cri-
teria of the International Workshop on CLL (IW-CLL) (11). In 
mantle cell lymphoma, swelling of lymph nodes are usually pres-
ent and gastrointestinal tract involvement occurs in a very high 
percentage and the majority of patients have genetic abnormal-
ities such as t(11:14)(q13;q32) (3, 12). This patient did not have 
lymphadenopathy and extranodal involvement in PET-CT and 
also did not have chromosome abnormalities. Instead of these 
characteristics of other B-cell lymphoproliferative disorders, 
this patient complained of hematuria, pretibial pitting edema, 
numbness of hand and foot in cold weather, and visual distur-
bance (13).  
  Renal involvement of WM is a rare manifestation, but a wide Kim YL, et al.  •  Waldenstrom Macroglobulinemia 
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spectrum of renal lesions is observed. After the first description 
of human renal lesions associated with deposition of monoclo-
nal lights chains, several renal complications have been report-
ed (7). WM-related nephropathies are characteristic intracapil-
lary deposits of IgM. In renal biopsy of our patient, we found 
pseudothrombi and subendothelial hyaline deposits with stained 
IgM and subendothelial and mesangial electron dense deposits 
revealing microtubular structures on electron microscopy com-
patible with cryoglobulinemic nephropathy (14). Serum cryo-
globulin of this patient was positive. Although there are a num-
ber of systemic conditions associated with cryoglobulinemia, 
including hepatitis C, lymphoproliferative disorders, infections, 
systemic lupus erythematosus (SLE) and other collagen vascu-
lar diseases, this patient was not associated with them. In WM, 
cryoglobulinemic glomerulonephropathy is a very rare renal 
disease which was reported in only 2 cases worldwide (7, 8).
  In addition to renal disease, the patient complained of visual 
disturbance. Ophthalamic examination showed vascular seg-
mentation and dilatation of the retinal veins. These revealed 
hyperviscosity syndrome (6). Hyperviscosity is a main feature 
in WM patients, and is due to the excess of IgM paraproteins. 
The relationship between serum viscosity and clinical manifes-
tations is not precise, and a general absolute value for viscosity 
at which hyperviscosity becomes clinically relevant does not 
exist (15). And it is difficult to use commercial check of viscosity 
in Korea, so we couldn’t run the tape over serum viscosity level. 
  WM usually follows a relatively indolent course with a medi-
an survival ranging from 60 to 120 months in different series 
(16). However, in some patients the disease may be more aggres-
sive (16). Several analyses have identified variables that may be 
associated with a worse prognosis. These include advanced age, 
cytopenia(s), hypoalbuminemia, elevated serum β2-microglo-
bulin, high IgM, poor performance status, B-symptoms or sple-
nomegaly. An International Prognositc Scoring System for WM 
(IPSSWM) was formulated based on 5 adverse covariates: age  
> 65 yr, hemoglobin less than or equal to 11.5 g/dL, platelet count 
less than or equal to 100,000/μL, β2-microglobulin more than  
3 mg/L, and serum monoclonal protein concentration more 
than 7.0 g/dL. The risk group is categorized as having low, inter-
mediate, high risk and five-year survival rates of these groups 
are 87%, 68%, and 36% respectively (17). Meanwhile, the indi-
cations for immediate therapy are disease-related cytopenias, 
bulky adenopathy or organomegaly, symptomatic hyperviscos-
ity, severe neuropathy, amyloidosis, cryoglobulinemia, cold ag-
glutinin disease, or evidence of disease transformation (13). 
There is no standard therapy for the treatment of symptomatic 
WM. Recent studies recommended the combination of ritux-
imab with nucleoside analogs and/or alkylating agents or with 
cyclophosphamide-based therapies, or the combination of ritux-
imab with thalidomide (13). An alternative frontline regimen 
can be considered along with bortezomib, alemtuzumab and 
stem cell transplantation. Newer agents, such as bendamustine 
and everolimus, can also be considered in the treatment of WM 
(6). According to IPSSWM, our patient is high risk group based 
on hemoglobin, platelet count and β2-microglobulin level. How-
ever, at present, no data suggest that new targeted therapies may 
overcome an adverse prognostic factor in WM and rituximab-
based chemotherapy has economic problem in Korea. So we 
treated this patient with CHOP chemotherapy and after the treat-
ment, the patient was in complete remission.  
  In conclusion, WM associated with CD5+ LPL and presented 
as cryoglobulinemic glomerulonephropathy is very rare, so clin-
ical features are important for differential diagnosis in CD5+ B-
cell lymphoproliferative disorders. Conventional chemothera-
py with CHOP is effective in symptomatic high risk group with 
cryoglobulinemia in WM. 
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